BCM
MXCT icon

Bridgeway Capital Management’s MaxCyte MXCT Stock Holding History

Bridgeway Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,800
Closed -$203K – 1289
2025
Q4 		$203K Sell
130,800
-50,000
-28% -$79.9K ﹤0.01% 1016
2025
Q3 		$286K Buy
180,800
+55,800
+45% +$97K 0.01% 939
2025
Q2 		$273K Buy
+125,000
New +$303K 0.01% 890
2023
Q1 		– Sell
-101,200
Closed -$553K – 1411
2022
Q4 		$553K Hold
101,200
– – 0.01% 867
2022
Q3 		$658K Hold
101,200
– – 0.02% 825
2022
Q2 		$479K Buy
+101,200
New +$498K 0.01% 884

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Bridgeway Capital Management's MXCT Position: Q1 2026 in Review

Bridgeway Capital Management sold out of MaxCyte (MXCT) in Q1 2026, closing a stake of 130,800 shares — an estimated $203K sold.

Bridgeway Capital Management first reported a position in MXCT in Q2 2022 and held it in 6 quarters. The position peaked at $658K in Q3 2022. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Bridgeway Capital Management reported no remaining MaxCyte position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 130,800 MaxCyte shares in Q1 2026, an estimated $203K.
  • Bridgeway Capital Management first reported a position in MaxCyte in Q2 2022 and held it in 6 quarters.
  • Bridgeway Capital Management's MaxCyte position peaked at $658K in Q3 2022.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.